- life sciences/pharma sector
-
7th Annual Commercial Translation of Regenerative Medicine
Excelling in Reimbursement Strategies and Penetrating the Market with Breakthrough Funding and Investment Ideas
Event Date: 3-4 Dec 2009
Location: NH Harrington Hall, London, UK
- key conference topics
-
- Develop winning reimbursement strategies
- Gain insight into new Advanced Therapies Medicinal Prodicts (ATMP) Regulation
- Master your collaboration with business partners and investors
- Scrutinise recent breakthroughs in regenerative medicine - Lessons to be learnt
- Understand how to translate regenerative medicine to the bedside with minimum regulatory and financial issues
- key conference features
-
- • Johnson and Johnson demystifying the pharmaceutical company’s point of view and its role in regenerative medicine
- • Paolo Macchiarini, Hospital Clinic of Barcelona discovering ways to bridge the gap between scientists and the industry - Getting insight into the Claudia’s case
- • Cellerix examining ways to fulfil the promise of adult stem cells therapeutics
- • Pluristem Therapeutics Inc developing clinical trial standardisation as a process and overcoming regulatory hurdles
- conference focus
-
Regenerative medicine is a rapidly growing field of biomedicine that has already proven its significance and is forecasted to Regenerative medicine is a rapidly growing field of biomedicine that has already proven its significance and is forecasted to play a key role in the health care system of the future. In the meantime, many questions still remain unanswered as regenerative medicine has entered a phase where in parallel with great breakthroughs there is increasing focus on the requirements for successful commercialisation.
This marcus evans conference brings together key industry, academia and regulatory experts to give a clear insight into the technologies and therapies that are nearing the market. And experts from the industry will present case studies focusing on the regulatory hurdles to overcome to guarantee commercial success.